These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 38579140)

  • 21. Ponatinib: A new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Shamroe CL; Comeau JM
    Ann Pharmacother; 2013 Nov; 47(11):1540-6. PubMed ID: 24265264
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Role of STAT5 in Tyrosine Kinase Inhibitor (IMATINIB) Resistance in CML Patients.
    Putri A; Rinaldi I; Louisa M; Koesnoe S
    Acta Med Indones; 2019 Oct; 51(4):348-352. PubMed ID: 32041920
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors.
    Redaelli S; Mologni L; Rostagno R; Piazza R; Magistroni V; Ceccon M; Viltadi M; Flynn D; Gambacorti-Passerini C
    Am J Hematol; 2012 Nov; 87(11):E125-8. PubMed ID: 23044928
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A molecular and biophysical comparison of macromolecular changes in imatinib-sensitive and imatinib-resistant K562 cells exposed to ponatinib.
    Yandim MK; Ceylan C; Elmas E; Baran Y
    Tumour Biol; 2016 Feb; 37(2):2365-78. PubMed ID: 26373734
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hypoxia-inducible factor 1α inhibitor induces cell death via suppression of BCR-ABL1 and Met expression in BCR-ABL1 tyrosine kinase inhibitor sensitive and resistant chronic myeloid leukemia cells.
    Tsubaki M; Takeda T; Matsuda T; Kimura A; Tanaka R; Nagayoshi S; Hoshida T; Tanabe K; Nishida S
    BMB Rep; 2023 Feb; 56(2):78-83. PubMed ID: 36195570
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting STAT5 or STAT5-Regulated Pathways Suppresses Leukemogenesis of Ph+ Acute Lymphoblastic Leukemia.
    Minieri V; De Dominici M; Porazzi P; Mariani SA; Spinelli O; Rambaldi A; Peterson LF; Porcu P; Nevalainen MT; Calabretta B
    Cancer Res; 2018 Oct; 78(20):5793-5807. PubMed ID: 30154155
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel HDAC inhibitor MAKV-8 and imatinib synergistically kill chronic myeloid leukemia cells via inhibition of BCR-ABL/MYC-signaling: effect on imatinib resistance and stem cells.
    Lernoux M; Schnekenburger M; Losson H; Vermeulen K; Hahn H; Gérard D; Lee JY; Mazumder A; Ahamed M; Christov C; Kim DW; Dicato M; Bormans G; Han BW; Diederich M
    Clin Epigenetics; 2020 May; 12(1):69. PubMed ID: 32430012
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Codelivery of Ponatinib and SAR302503 by Active Bone-Targeted Polymeric Micelles for the Treatment of Therapy-Resistant Chronic Myeloid Leukemia.
    Mu CF; Xiong Y; Bai X; Sheng YJ; Cui J
    Mol Pharm; 2017 Jan; 14(1):274-283. PubMed ID: 27957861
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ASP210: a potent oligonucleotide-based inhibitor effective against TKI-resistant CML cells.
    Nemethova V; Babiakova P; Teglasova B; Uhelska L; Babelova A; Selc M; Jakic K; Mitrovsky O; Myslivcova D; Zackova M; Poturnayova A; Batorova A; Drgona L; Razga F
    Am J Physiol Cell Physiol; 2024 Jul; 327(1):C184-C192. PubMed ID: 38826137
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
    Ferri C; Bianchini M; Bengió R; Larripa I
    Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The outcomes of patients with chronic myeloid leukemia treated with third-line BCR::ABL1 tyrosine kinase inhibitors.
    Jabbour EJ; Sasaki K; Haddad FG; Issa GC; Garcia-Manero G; Kadia TM; Jain N; Yilmaz M; DiNardo CD; Patel KP; Kanagal-Shamanna R; Champlin R; Khouri IF; Dellasala S; Pierce SA; Kantarjian H
    Am J Hematol; 2023 Apr; 98(4):658-665. PubMed ID: 36683287
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anthelmintic niclosamide suppresses transcription of BCR-ABL fusion oncogene via disabling Sp1 and induces apoptosis in imatinib-resistant CML cells harboring T315I mutant.
    Jin B; Wang C; Shen Y; Pan J
    Cell Death Dis; 2018 Jan; 9(2):68. PubMed ID: 29358661
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-Term Follow-Up in Patients With Chronic Myeloid Leukemia Treated With Ponatinib in a Real-World Cohort: Safety and Efficacy Analysis.
    Mela Osorio MJ; Moiraghi B; Osycka MV; Pavlovsky MA; Varela AI; Bendek Del Prete GE; Tosin MF; Pérez MA; Riva ME; Berrios RR; Fernández I; Sackmann Massa F; Giere I; Sighel C; Pavlovsky C
    Clin Lymphoma Myeloma Leuk; 2024 Mar; 24(3):158-164. PubMed ID: 37973457
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New Insights into the Molecular Resistance Mechanisms of Chronic Myeloid Leukemia.
    Huang R; Kang Q; Liu H; Li Y
    Curr Cancer Drug Targets; 2016; 16(4):323-45. PubMed ID: 26391311
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dual inhibition of STAT3 and STAT5 may overcome imatinib resistance in chronic myeloid leukemia.
    Yin L; Xu J; Wu W; Niu M; Li Z; Zhu F; Xu K
    Hematology; 2023 Dec; 28(1):2224625. PubMed ID: 37345979
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An evaluation of ponatinib as a therapy in adult patients with resistant/intolerant chronic-phase chronic myeloid leukemia.
    Yang J; Surapaneni M; Schiffer CA
    Expert Rev Hematol; 2022 May; 15(5):393-402. PubMed ID: 35544670
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ponatinib-review of historical development, current status, and future research.
    Kantarjian HM; Chifotides HT; Haddad FG; Short NJ; Loghavi S; Jabbour E
    Am J Hematol; 2024 Aug; 99(8):1576-1585. PubMed ID: 38727135
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting FLT3-TAZ signaling to suppress drug resistance in blast phase chronic myeloid leukemia.
    Shin JE; Kim SH; Kong M; Kim HR; Yoon S; Kee KM; Kim JA; Kim DH; Park SY; Park JH; Kim H; No KT; Lee HW; Gee HY; Hong S; Guan KL; Roe JS; Lee H; Kim DW; Park HW
    Mol Cancer; 2023 Nov; 22(1):177. PubMed ID: 37932786
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring.
    Jabbour E; Kantarjian H
    Am J Hematol; 2022 Sep; 97(9):1236-1256. PubMed ID: 35751859
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia.
    Zabriskie MS; Eide CA; Tantravahi SK; Vellore NA; Estrada J; Nicolini FE; Khoury HJ; Larson RA; Konopleva M; Cortes JE; Kantarjian H; Jabbour EJ; Kornblau SM; Lipton JH; Rea D; Stenke L; Barbany G; Lange T; Hernández-Boluda JC; Ossenkoppele GJ; Press RD; Chuah C; Goldberg SL; Wetzler M; Mahon FX; Etienne G; Baccarani M; Soverini S; Rosti G; Rousselot P; Friedman R; Deininger M; Reynolds KR; Heaton WL; Eiring AM; Pomicter AD; Khorashad JS; Kelley TW; Baron R; Druker BJ; Deininger MW; O'Hare T
    Cancer Cell; 2014 Sep; 26(3):428-442. PubMed ID: 25132497
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.